Gilead Sciences (GILD) 89.84 $GILD
This Week in Biotech: Puma Sprints, Gilead Sweeps, and Inovio Hits the Mark
Sean Williams, The Motley Fool - Motley Fool - Sat Jul 26, 12:32PM CDT
With the SPDR S&P Biotech Index up 22% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Final Glance: Biotechnology companies
AP - Fri Jul 25, 5:12PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Fri Jul 25, 12:42PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
AbbVie Beats Earnings Views, Sees Slower Humira Gain
at Investor's Business Daily - Fri Jul 25, 10:46AM CDT
Big pharma AbbVie (ABBV) beat analysts' Q2 estimates as its lead drug Humira grew sharply, though the company said this would slow down and affirmed its full-year guidance. The stock fell fractionally in morning trading on the stock market today....
Early Glance: Biotechnology companies
AP - Fri Jul 25, 9:21AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Uptrend Call Working As Gilead Sciences Stock Rises 24.0% (GILD)
Comtex SmarTrend(R) - Fri Jul 25, 9:17AM CDT
SmarTrend identified an Uptrend for Gilead Sciences (NASDAQ:GILD) on April 22nd, 2014 at $72.56. In approximately 3 months, Gilead Sciences has returned 23.99% as of today's recent price of $89.96.
Why Gilead Stock's Newest Drug Approval Isn't a Gamechanger
Brian Orelli, The Motley Fool - Motley Fool - Fri Jul 25, 7:30AM CDT
Gilead Sciences is finally an oncology company. It's been years in the making . On Wednesday, the biotech got Zydelig approved to treat three different B-cell blood cancers: chronic lymphocytic leukemia, follicular B-cell non-Hodgkin lymphoma,...
European CHMP Adopts Positive Opinion for Gilead's Zydelig(R) (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Business Wire - Fri Jul 25, 6:24AM CDT
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company's Marketing Authorization Application (MAA) for Zydelig(R) (idelalisib 150 mg film-coated tablets), a first-in-class treatment for patients with chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL), the most common subtype of indolent non-Hodgkin lymphoma (iNHL). The CHMP opinion supports the use of Zydelig in combination with rituximab for the treatment of adult patients with CLL who have received at least one prior therapy or, as first-line treatment in CLL patients in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy and also as monotherapy for the treatment of adult patients with FL that is refractory to two prior lines of treatment. The CHMP's recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 countries of the European Union (EU).
Why Gilead Sciences, inc. Stock Was Flat Today
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Jul 24, 6:07PM CDT
Gilead Sciences turned in an incredible quarter yesterday, with revenue of $6.5 billion beating analyst expectations by 12% and more than doubling the year-ago quarter. The difference in earnings was even starker: Adjusted EPS of $2.36...
Celgene, Alexion Beat Estimates, But Biotechs Fall
at Investor's Business Daily - Thu Jul 24, 4:07PM CDT
Big-cap biotechs Celgene and Alexion Pharmaceuticals modestly beat Q2 estimates and raised their guidance early Thursday, but their shares tumbled as Wall Street seemed to turn against the sector. Celgene's (CELG) Q2 earnings rose 18% over the...
3 Crucial Quotes From Gilead Sciences Stock
Todd Campbell, The Motley Fool - Motley Fool - Thu Jul 24, 4:05PM CDT
Gilead Sciences is a long-standing leader in HIV treatment, but its sales of its hepatitis C drug Sovaldi that's driving the company's revenue surge. While Sovaldi's sales are soaring, investors are right to wonder if the drug's break neck...
Avella Chosen as Specialty Pharmacy Partner for Zydelig(R)
Newsfile Corp - Thu Jul 24, 3:29PM CDT
full story)
What Gilead Stock's Latest Blockbuster Approval Means for Investors
Todd Campbell, The Motley Fool - Motley Fool - Thu Jul 24, 3:01PM CDT
Source: Gilead Sciences Gilead Sciences has won approval for its promising drug Zydelig in three important cancer indications. As a combination treatment alongside Roche's top selling Rituxan, the FDA green-light puts Zydelig head-to-head...
Alexion Pharmaceuticals Q2 Earnings In Line; Revises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 2:45PM CDT
Alexion (ALXN) reported in line earnings in the second quarter.
3 Game-Changing Stories That Shook Investors: Inovio Pharmaceuticals, Gilead Sciences, and GlaxoSmit
George Budwell, The Motley Fool - Motley Fool - Thu Jul 24, 1:05PM CDT
The health care sector exploded with major news events yesterday, fueled by second-quarter earnings, clinical trial updates, and even unexpected regulatory events. Given that the day's headlines seemed to be dominated by Puma Biotechnology 's...
Healthcare Spending to Trend Up in 2015: 3 Healthcare Fund Picks - Best of Funds
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 12:48PM CDT
The rise in healthcare spending, if true, will increase business for hospitals, diagnostic centers and healthcare related industry. Eventually, the healthcare industry should benefit and help healthcare funds be better investment potential.
Most active Nasdaq-traded stocks
AP - Thu Jul 24, 12:23PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
3 Stocks Improving Performance Of The Health Care Sector
at The Street - Thu Jul 24, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
This Week in Biotech: Puma Sprints, Gilead Sweeps, and Inovio Hits the Mark
Sean Williams, The Motley Fool - Motley Fool - Sat Jul 26, 12:32PM CDT
With the SPDR S&P Biotech Index up 22% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Final Glance: Biotechnology companies
AP - Fri Jul 25, 5:12PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Fri Jul 25, 12:42PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
AbbVie Beats Earnings Views, Sees Slower Humira Gain
at Investor's Business Daily - Fri Jul 25, 10:46AM CDT
Big pharma AbbVie (ABBV) beat analysts' Q2 estimates as its lead drug Humira grew sharply, though the company said this would slow down and affirmed its full-year guidance. The stock fell fractionally in morning trading on the stock market today....
Early Glance: Biotechnology companies
AP - Fri Jul 25, 9:21AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Uptrend Call Working As Gilead Sciences Stock Rises 24.0% (GILD)
Comtex SmarTrend(R) - Fri Jul 25, 9:17AM CDT
SmarTrend identified an Uptrend for Gilead Sciences (NASDAQ:GILD) on April 22nd, 2014 at $72.56. In approximately 3 months, Gilead Sciences has returned 23.99% as of today's recent price of $89.96.
Why Gilead Stock's Newest Drug Approval Isn't a Gamechanger
Brian Orelli, The Motley Fool - Motley Fool - Fri Jul 25, 7:30AM CDT
Gilead Sciences is finally an oncology company. It's been years in the making . On Wednesday, the biotech got Zydelig approved to treat three different B-cell blood cancers: chronic lymphocytic leukemia, follicular B-cell non-Hodgkin lymphoma,...
European CHMP Adopts Positive Opinion for Gilead's Zydelig(R) (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Business Wire - Fri Jul 25, 6:24AM CDT
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company's Marketing Authorization Application (MAA) for Zydelig(R) (idelalisib 150 mg film-coated tablets), a first-in-class treatment for patients with chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL), the most common subtype of indolent non-Hodgkin lymphoma (iNHL). The CHMP opinion supports the use of Zydelig in combination with rituximab for the treatment of adult patients with CLL who have received at least one prior therapy or, as first-line treatment in CLL patients in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy and also as monotherapy for the treatment of adult patients with FL that is refractory to two prior lines of treatment. The CHMP's recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 countries of the European Union (EU).
Why Gilead Sciences, inc. Stock Was Flat Today
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu Jul 24, 6:07PM CDT
Gilead Sciences turned in an incredible quarter yesterday, with revenue of $6.5 billion beating analyst expectations by 12% and more than doubling the year-ago quarter. The difference in earnings was even starker: Adjusted EPS of $2.36...
Celgene, Alexion Beat Estimates, But Biotechs Fall
at Investor's Business Daily - Thu Jul 24, 4:07PM CDT
Big-cap biotechs Celgene and Alexion Pharmaceuticals modestly beat Q2 estimates and raised their guidance early Thursday, but their shares tumbled as Wall Street seemed to turn against the sector. Celgene's (CELG) Q2 earnings rose 18% over the...
3 Crucial Quotes From Gilead Sciences Stock
Todd Campbell, The Motley Fool - Motley Fool - Thu Jul 24, 4:05PM CDT
Gilead Sciences is a long-standing leader in HIV treatment, but its sales of its hepatitis C drug Sovaldi that's driving the company's revenue surge. While Sovaldi's sales are soaring, investors are right to wonder if the drug's break neck...
Avella Chosen as Specialty Pharmacy Partner for Zydelig(R)
Newsfile Corp - Thu Jul 24, 3:29PM CDT
full story)
What Gilead Stock's Latest Blockbuster Approval Means for Investors
Todd Campbell, The Motley Fool - Motley Fool - Thu Jul 24, 3:01PM CDT
Source: Gilead Sciences Gilead Sciences has won approval for its promising drug Zydelig in three important cancer indications. As a combination treatment alongside Roche's top selling Rituxan, the FDA green-light puts Zydelig head-to-head...
Alexion Pharmaceuticals Q2 Earnings In Line; Revises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 2:45PM CDT
Alexion (ALXN) reported in line earnings in the second quarter.
3 Game-Changing Stories That Shook Investors: Inovio Pharmaceuticals, Gilead Sciences, and GlaxoSmit
George Budwell, The Motley Fool - Motley Fool - Thu Jul 24, 1:05PM CDT
The health care sector exploded with major news events yesterday, fueled by second-quarter earnings, clinical trial updates, and even unexpected regulatory events. Given that the day's headlines seemed to be dominated by Puma Biotechnology 's...
Healthcare Spending to Trend Up in 2015: 3 Healthcare Fund Picks - Best of Funds
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 12:48PM CDT
The rise in healthcare spending, if true, will increase business for hospitals, diagnostic centers and healthcare related industry. Eventually, the healthcare industry should benefit and help healthcare funds be better investment potential.
Most active Nasdaq-traded stocks
AP - Thu Jul 24, 12:23PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
3 Stocks Improving Performance Of The Health Care Sector
at The Street - Thu Jul 24, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
